 September 08, 2025

Daiichi Sankyo, a Japanese pharmaceutical company, has announced the official commencement of construction on a new antibody-drug conjugate (ADC) manufacturing facility in Shanghai’s Zhangjiang area, with a total investment of approximately RMB 1.1 billion. As one of China’s first pilot projects for cross-border, segmented manufacturing of biologics, this initiative will be rooted in the Chinese market to establish a localized ADC production base, significantly enhancing the domestic supply capacity of ADC innovative drugs.